TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21803976

Group type: EXPERIMENTAL
Intervention: NaClO(3) 60 mg·kg of BW(‐1)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: NaClO(3) 90 mg·kg of BW(‐1)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: NaClO(3) 150 mg·kg of BW(‐1)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: NaClO(3) 300 mg·kg of BW(‐1)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: NaClO(3) 450 mg·kg of BW(‐1)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (saline NaCl, 30 mg·kg of BW(‐1) for lambs; 150 mg·kg of BW(‐1) for ewes)
Number of subjects: 76
Study: 19486475

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Dynamic stretching
Number of subjects: 10

Group type: COMPARATOR
Intervention: Non-stretching (control)
Number of subjects: 10
Study: 19398935

Group type: EXPERIMENTAL
Intervention: (32)P‐chromic phosphate colloids (32)P‐CP) injection during surgery
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (tumor resections only)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: (32)P‐CP injection
Number of subjects: 73
Study: 16416607

Group type: EXPERIMENTAL
Intervention: Imiquimod 5% cream applied to one surgical wound
Number of subjects: 20

Group type: COMPARATOR
Intervention: Vehicle cream applied to the second surgical wound (Control)
Number of subjects: 20
Study: 12584537

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 186

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 186
Study: 10593714

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination (FDC) formulations of rifampicin, isoniazid and pyrazinamide
Number of subjects: 20

Group type: COMPARATOR
Intervention: Separate formulations of rifampicin, isoniazid and pyrazinamide
Number of subjects: 20
Study: 8709658

Group type: EXPERIMENTAL
Intervention: Intervention letters sent to physicians for 174 patients
Number of subjects: 335

Group type: COMPARATOR
Intervention: Control group (no intervention letters)
Number of subjects: 335
Study: 1750473

Group type: EXPERIMENTAL
Intervention: Combination of ampicillin‐sulbactam and indomethacin
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 7066144

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 5 micrograms kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate 7.5 micrograms kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Atropine 10 micrograms kg‐1
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Atropine 15 micrograms kg‐1
Number of subjects: 80
Study: 30445989

Group type: EXPERIMENTAL
Intervention: Health education regarding edible oils for four consecutive weeks (Group A)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Blank control (Group B)
Number of subjects: 800
Study: 26993737

Group type: EXPERIMENTAL
Intervention: Self-affirmation (writing about personally relevant values)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control task (writing about values relevant to another person)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-affirmation
Number of subjects: 0
Study: 23900406

Group type: EXPERIMENTAL
Intervention: Phonological working memory tasks
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Visuospatial working memory tasks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control conditions with minimal working memory demands
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Central executive and phonological storage/rehearsal subsystems
Number of subjects: 35
Study: 22318635

Group type: EXPERIMENTAL
Intervention: Rehabilitation study group (not specified in detail)
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Week 1 stress
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Week 26 sleep
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Female gender and younger age
Number of subjects: 195

Group type: EXPERIMENTAL
Intervention: Week 1 anxiety, depression, and stress; week 26 sleeping; rehabilitation study group
Number of subjects: 195

Group type: COMPARATOR
Intervention: Study group
Number of subjects: 195
Study: 20089221

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine, 600 mg every 12 h intravenously
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 81
Study: 17822820

Group type: EXPERIMENTAL
Intervention: Lithium treatment
Number of subjects: 161
Study: 15641045

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 200

Group type: COMPARATOR
Intervention: Calcium-based phosphate binders
Number of subjects: 200
Study: 15228256

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine (SP)
Number of subjects: 29
Study: 11933280

Group type: EXPERIMENTAL
Intervention: Huntleigh Nimbus 3 in conjunction with the Aura cushion (Group A)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Pegasus Cairwave Therapy System in conjunction with the Proactive 2 Seating cushion (Group B)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 141
Study: 8895286

Group type: EXPERIMENTAL
Intervention: Variable-dose PCA (VDPCA) - 0.5, 1.0, and 1.5 mg boluses of morphine
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fixed-dose PCA (FDPCA) - 1.0 mg of morphine
Number of subjects: 60
Study: 2070384

Group type: EXPERIMENTAL
Intervention: Duraphat varnish treatments 3 times a week, once a year
Number of subjects: 160

Group type: COMPARATOR
Intervention: Duraphat varnish treatments every 6 months
Number of subjects: 160
Study: 6364775

Group type: EXPERIMENTAL
Intervention: High amylose rice (23 to 25% amylose)
Number of subjects: 33

Group type: COMPARATOR
Intervention: 0% amylose rice
Number of subjects: 33
Study: 31128770

Group type: EXPERIMENTAL
Intervention: Higher serum uromodulin (sUMOD) levels (mean sUMOD level was 127±64ng/mL)
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Higher serum uromodulin (sUMOD) levels
Number of subjects: 933
Study: 31261494

Group type: EXPERIMENTAL
Intervention: Eteplirsen 30 or 50 mg/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Eteplirsen treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 28100282

Group type: EXPERIMENTAL
Intervention: Single-strength group (SS, SMX/TMP of 400/80 mg daily)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Half-strength group (HS, SMX/TMP of 200/40 mg daily)
Number of subjects: 183

Group type: EXPERIMENTAL
Intervention: Escalation group (ES, started with 40/8 mg daily, increasing to 200/40 mg daily)
Number of subjects: 183
Study: 26470637

Group type: EXPERIMENTAL
Intervention: Calcium supplement (1600 mg) and vitamin D3 (1000 IU) ingested prior to cycling for 5 months
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 17
Study: 23224330

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) treatment
Number of subjects: 508
Study: 21242642

Group type: EXPERIMENTAL
Intervention: Simvastatin (SIM) in combination with Losartan (LOS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Losartan (LOS)
Number of subjects: 0
Study: 18428069

Group type: EXPERIMENTAL
Intervention: Tai-Kang-Ning (TKN) capsule
Number of subjects: 64

Group type: COMPARATOR
Intervention: Lofexidine
Number of subjects: 64
Study: 16611950

Group type: EXPERIMENTAL
Intervention: Telithromycin (800 mg daily for 10 days)
Number of subjects: 278

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Telithromycin
Number of subjects: 278
Study: 12962869

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tacrolimus (Tac) with mycophenolate mofetil (MMF) and steroids
Number of subjects: 0
Study: 10849040

Group type: EXPERIMENTAL
Intervention: L-5-hydroxytryptophan (5-HTP), 300 mg per day
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 9322355

Group type: EXPERIMENTAL
Intervention: Mitomycin C (10 mg/m2 i.v. day 1), Vinblastine (5 mg/m2 i.v. day 1 and 15), Amifostine (910 mg/m2 in short i.v. infusion prior to MMC)
Number of subjects: 6
Study: 8401500

Group type: EXPERIMENTAL
Intervention: Nested PCR strategy for sex determination at the single cell level by simultaneous amplification of ZFX and ZFY genes
Number of subjects: 194
Study: 3536563

Group type: EXPERIMENTAL
Intervention: Almitrine bismesylate (ABM) taken orally
Number of subjects: 490

Group type: COMPARATOR
Intervention: Conventional means (control group)
Number of subjects: 490
Study: 31074164

Group type: COMPARATOR
Intervention: Traditional supervisor-led clinical session (Group A)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: YouTube videos of high educational quality (Group B)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Self-selected YouTube videos (Group C)
Number of subjects: 71
Study: 29198060

Group type: EXPERIMENTAL
Intervention: MDMA administration
Number of subjects: 124
Study: 26238598

Group type: EXPERIMENTAL
Intervention: Heinrichs-Carpenter Quality of Life Scale (QLS) total score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical Global Impressions of Severity (CGI-S)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QLS improvers (QLS total score increased ≥ six points)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: QLS domains: 'Interpersonal relations' and 'Intrapsychic foundations'
Number of subjects: 0
Study: 1446958

Group type: EXPERIMENTAL
Intervention: Indolidan (IN) administered i.v. at 1,180 +/- 340 micrograms (15 micrograms/kg) over two hours
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Indolidan (IN) administered p.o. at 231 +/- 44 micrograms
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Indolidan (IN)
Number of subjects: 12
Study: 22846396

Group type: EXPERIMENTAL
Intervention: 7.5 μg dose of H1N1 vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Booster vaccination with licensed trivalent seasonal influenza vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H1N1 vaccine
Number of subjects: 0
Study: 19937106

Group type: EXPERIMENTAL
Intervention: Planning intervention (physical activity guidelines, local municipal healthy active living guide + planning material)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Standard condition (received physical activity guidelines and a local municipal healthy active living guide)
Number of subjects: 85
Study: 18708731

Group type: EXPERIMENTAL
Intervention: S-1 + PSK
Number of subjects: 20

Group type: COMPARATOR
Intervention: S-1
Number of subjects: 20
Study: 15781521

Group type: EXPERIMENTAL
Intervention: Breathing circuit leak test with non-zero basal flow (BF) of oxygen
Number of subjects: 25

Group type: COMPARATOR
Intervention: Breathing circuit leak test without non-zero basal flow (BF) of oxygen
Number of subjects: 25
Study: 12914507

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (0.3%) eardrops, 5 drops twice daily for 9 days
Number of subjects: 147

Group type: COMPARATOR
Intervention: Framycetin (0.5%), gramicidin, dexamethasone (FGD) eardrops, 5 drops twice daily for 9 days
Number of subjects: 147
Study: 10503681

Group type: EXPERIMENTAL
Intervention: Nebulized budesonide (800 microg) and nebulized salbutamol (0.15 mg/kg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Oral prednisolone (2 mg/kg) and nebulized salbutamol (0.15 mg/kg)
Number of subjects: 80
Study: 8759565

Group type: EXPERIMENTAL
Intervention: Lornoxicam 8 mg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Lornoxicam 4 mg
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Tramadol 50 mg
Number of subjects: 78

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study: 1922207

Group type: EXPERIMENTAL
Intervention: Intravesical doxorubicin
Number of subjects: 262

Group type: COMPARATOR
Intervention: Bacille Calmette-Guérin (BCG)
Number of subjects: 262
Study: 7191832

Group type: EXPERIMENTAL
Intervention: Low concentrated amino acid‐carbohydrate solution (PE 900 with 25 g x 1(‐1) amino acids and 50 g x 1(‐1) Polyols)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low concentrated amino acid‐carbohydrate solution (PE 900)
Number of subjects: 0
Study: 31678833

Group type: EXPERIMENTAL
Intervention: Active cannabis (12.5% THC)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Low THC cannabis (12.5% THC)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: High THC cannabis (12.5% THC)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Placebo cannabis (0.009% THC)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: All groups (including placebo)
Number of subjects: 91
Study: 28196279

Group type: EXPERIMENTAL
Intervention: Head lift exercise (HLE), performed 5 days a week for 4 weeks (total of 20 sessions).
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group received the same conventional dysphagia therapy without HLE.
Number of subjects: 27
Study: 26490493

Group type: EXPERIMENTAL
Intervention: High adherence to Mediterranean diet (aMeDi score of 6-9)
Number of subjects: 2525

Group type: EXPERIMENTAL
Intervention: High adherence to Mediterranean diet (aMeDi score) among subjects carrying the CFH Y402H nonrisk (T) allele
Number of subjects: 2525

Group type: EXPERIMENTAL
Intervention: High adherence to Mediterranean diet (aMeDi score) among subjects homozygous for the risk (C) allele
Number of subjects: 2525
Study: 24041858

Group type: EXPERIMENTAL
Intervention: Aerosal halotherapy
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 18209608

Group type: EXPERIMENTAL
Intervention: Immediate serial casting (same day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Delayed serial casting (4 weeks later)
Number of subjects: 12
Study: 15482056

Group type: EXPERIMENTAL
Intervention: Domestic cat meows
Number of subjects: 0

Group type: COMPARATOR
Intervention: Wild cat vocalizations
Number of subjects: 0
Study: 11131342

Group type: EXPERIMENTAL
Intervention: Procaine penicillin intramuscularly for 4-7 days
Number of subjects: 154

Group type: COMPARATOR
Intervention: Cefuroxime intravenously for 4-7 days
Number of subjects: 154
Study: 9291414

Group type: EXPERIMENTAL
Intervention: Topical sodium cromoglycate
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 14
Study: 8318683

Group type: EXPERIMENTAL
Intervention: Recombinant erythropoietin
Number of subjects: 244

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 244
Study: 2872794

Group type: EXPERIMENTAL
Intervention: Hyaluronidase therapy (500 National Formulary units/kg intravenously every 6 hours for 48 hours)
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Hyaluronidase therapy
Number of subjects: 851
Study: 31437669

Group type: EXPERIMENTAL
Intervention: Preoperative microbiome analysis using 16S-23S rDNA Next Generation Sequencing (NGS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Preoperative nasal and perineal cultures
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Histological analysis of groin biopsies
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (patients without SSI)
Number of subjects: 10
Study: 29793800

Group type: EXPERIMENTAL
Intervention: Low-pressure sports compression tights (CT)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Track pants (CON)
Number of subjects: 33
Study: 26730183

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 100/25 mcg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tiotropium (TIO) 18 mcg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tiotropium (TIO)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both FF/VI and TIO
Number of subjects: 0
Study: 24552307

Group type: EXPERIMENTAL
Intervention: Resource priming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supportive resource priming
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adherence priming
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0
Study: 22152634

Group type: EXPERIMENTAL
Intervention: Manual K‐files (group M)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: PathFile rotary instruments (group PF)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Mtwo rotary instruments (group MT)
Number of subjects: 45
Study: 20660140

Group type: EXPERIMENTAL
Intervention: Experimental meningococcal serogroup B vaccine (five formulations, n = 25 in each group)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Experimental meningococcal serogroup B vaccine
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control (VA‐Mengoc‐BC, n = 25)
Number of subjects: 150
Study: 17372241

Group type: EXPERIMENTAL
Intervention: High perceived ambiguity about mammography recommendations
Number of subjects: 0
Study: 16326882

Group type: EXPERIMENTAL
Intervention: Continuous passive motion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard immobilisation in a cast
Number of subjects: 50
Study: 12196053

Group type: EXPERIMENTAL
Intervention: loratadine 10 mg/d
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: chlorpheniramine maleate 12 mg twice daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: loratadine and chlorpheniramine maleate
Number of subjects: 36
Study: 9527356

Group type: EXPERIMENTAL
Intervention: Toothpick impregnated in 4% NaF
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dentifrice containing 0.32% NaF
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Mouthrinse solution containing 0.025% NaF
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Tablet containing 0.55 mg NaF
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Commercial fluoride toothpicks and dental flosses
Number of subjects: 24

Group type: COMPARATOR
Intervention: Sampling procedure
Number of subjects: 24
Study: 7837388

Group type: EXPERIMENTAL
Intervention: Sequential regimen (four courses of doxorubicin followed by eight courses of CMF)
Number of subjects: 403

Group type: COMPARATOR
Intervention: Alternating regimen (two courses of CMF alternated with one course of doxorubicin)
Number of subjects: 403
Study: 2297344

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (n = 23)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Atenolol (n = 17)
Number of subjects: 40
Study: 694481

Group type: EXPERIMENTAL
Intervention: 20 mg/d tamoxifen by mouth
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: tamoxifen
Number of subjects: 158
Study: 31722650

Group type: EXPERIMENTAL
Intervention: Integrative cognitive-behavioral therapy (25 ± 3 sessions)
Number of subjects: 47
Study: 30853500

Group type: EXPERIMENTAL
Intervention: Early Start Denver Model (ESDM), an intensive, naturalistic developmental‐behavioural intervention program
Number of subjects: 48
Study: 28317510

Group type: EXPERIMENTAL
Intervention: 12-step facilitation (TSF) intervention: Stimulant Abuser Groups to Engage in 12-Step (STAGE-12)
Number of subjects: 471

Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 471
Study: 23929521

Group type: EXPERIMENTAL
Intervention: Emotion Management Training (EMT)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Social Skills Training (SST)
Number of subjects: 72

Group type: COMPARATOR
Intervention: No Treatment
Number of subjects: 72
Study: 23958293

Group type: EXPERIMENTAL
Intervention: PIVOT technique (interleaved pulsed arterial spin labeling and multi-echo gradient-recalled echo sequences)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PIVOT technique
Number of subjects: 10
Study: 21869685

Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg/d
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 19628206

Group type: EXPERIMENTAL
Intervention: 600 microg of sublingual misoprostol
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: 400 microg of sublingual misoprostol
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Intravenous oxytocin
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Intravenous methylergometrine
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Misoprostol groups
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Methylergometrine group
Number of subjects: 300

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 300
Study: 17255231

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine plus albendazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diethylcarbamazine
Number of subjects: 0
Study: 15482083

Group type: EXPERIMENTAL
Intervention: Consumption cue
Number of subjects: 40

Group type: COMPARATOR
Intervention: No-consumption cue
Number of subjects: 40
Study: 11678862

Group type: EXPERIMENTAL
Intervention: Montelukast (MT) 10 mg once a day
Number of subjects: 51

Group type: COMPARATOR
Intervention: Cetirizine (CET) 10 mg once a day
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 51
Study: 9759273

Group type: EXPERIMENTAL
Intervention: Subcutaneous epinephrine, 10 micrograms/kg (n = 28)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Subcutaneous terbutaline, 10 micrograms/kg (n = 26)
Number of subjects: 54
Study: 7840862

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 2894359

Group type: EXPERIMENTAL
Intervention: Fenoldopam (DA1 receptor agonist)
Number of subjects: 10
Study: 29351130

Group type: COMPARATOR
Intervention: Aerobic moderate-intensity cycling (AMC)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Low-volume time-based resistance exercise training (TRE)
Number of subjects: 28
Study: 27582175

Group type: EXPERIMENTAL
Intervention: Medication Management Review (MMR) service
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no MMR service)
Number of subjects: 160
Study: 23913094

Group type: EXPERIMENTAL
Intervention: Thulium laser resection of the prostate-tangerine technique (TmLRP-TT)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Transurethral resection of prostate (TURP)
Number of subjects: 96
Study: 23334802

Group type: EXPERIMENTAL
Intervention: Cuff pressure maintained at approximately 25 cm H2O throughout the operation (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Cuff pressure set to 25 cm H2O initially and monitored continuously without adjustment (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 90
Study: 20600478

Group type: EXPERIMENTAL
Intervention: AS03(B)-adjuvanted vaccine (1.9microg HA)
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: AS03(A)-adjuvanted vaccine (3.75microg HA)
Number of subjects: 157